North America: Intellectual Property

Subscribe
Intellectual property law and copyright law thought leadership, articles, podcasts, videos and webinars from expert sources across the legal world. Explore insights covering topics such as licensing and syndication, patent law, trade secrets and trademark law.
Article
Effective Filing Date Of Provisional And Non-Provisional Application Prior Art
The Federal Circuit vacated a PTAB decision on patent obviousness, establishing that a provisional application must provide written description support for at least one published claim to qualify as prior art under its earlier filing date. This ruling clarifies the requirements for claiming priority from provisional applications and impacts how patent practitioners should approach provisional filing strategies.
United States IP
OM
Oblon, McClelland, Maier & Neustadt, L.L.P
See more
Article
Texas Business Court Prohibits Foreign Attorneys From Accessing Protected Documents
The Texas Business Court recently clarified who qualifies as an attorney when dealing with confidential and attorney's eyes only designations in discovery. In a case involving alleged trade secret misappropriation between rival transformer manufacturers, the court examined whether attorneys from India representing the plaintiff in other matters could access protected documents in the Texas state court case...
United States Litigation
JW
Jones Walker
Article
A Spoonful Of Sugar | Bryan Sugar's AI Litigation Insights - August 2026
Courts have escalated from warnings to enforcement on AI hallucinations in legal filings, with seven sanctions issued in the first six days of August 2026 alone. IP litigators face heightened exposure due to citation-heavy briefs, complex multi-factor tests, and cross-jurisdictional AI disclosure requirements that now include bar referrals for unverified AI-generated content.
United States Technology
LB
Lewis Brisbois Bisgaard & Smith LLP
See more
Article
Les Marques De Commerce Pour Les Entreprises – 3e Partie : La Demande D’Enregistrement D’Une Marque De Commerce
Découvrez les facteurs clés pour optimiser votre stratégie d'enregistrement de marques de commerce : quelles marques protéger en priorité, dans quels territoires investir, et comment choisir entre les systèmes nationaux, régionaux ou internationaux. Explorez les avantages et inconvénients de chaque approche pour maximiser la protection de vos actifs de propriété intellectuelle tout en maîtrisant vos coûts.
Canada IP
SB
Smart & Biggar
See more
Article
China On The Move: China Reprices Clinical Data (Part One) — A New Exclusivity Architecture Takes Effect
On May 15, 2026, a substantial revision of China’s Implementing Regulations of the Drug Administration Law (the Regulations or Implementing Regulations) took effect, introducing, among other items, a formal data protection framework. On the same day, China’s National Medical Products Administration (NMPA) issued the Implementing Measures for Drug Trial Data Protection (the Measures), giving operational effect to the Regulations’ data-protection article for the first time since China accepted the underlying obligation upon World Trade Organization (WTO) accession.
United States Healthcare
GT
Greenberg Traurig, LLP
Article
Effective Filing Date Of Provisional And Non-Provisional Application Prior Art
The Federal Circuit vacated a PTAB decision on patent obviousness, establishing that a provisional application must provide written description support for at least one published claim to qualify as prior art under its earlier filing date. This ruling clarifies the requirements for claiming priority from provisional applications and impacts how patent practitioners should approach provisional filing strategies.
United States IP
OM
Oblon, McClelland, Maier & Neustadt, L.L.P
Article
Biocon Launches Aflibercept Biosimilar In The United States
Biocon Limited has commercially launched YESAFILI (aflibercept-jbvf), a biosimilar to Regeneron's EYLEA, in the United States following settlement agreements that lifted previous injunction barriers. This marks the second aflibercept biosimilar available in the U.S. market, entering a competitive landscape where patent litigation continues to shape biosimilar entry strategies. The launch follows a complex legal journey involving multiple jurisdictions and settlement negotiations that ultimately permitted ea
Worldwide Healthcare
GP
Goodwin Procter LLP
See more
See more